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AbstrACt
Objectives Nocturnal haemodialysis (NHD), characterised 
by 8-hour sessions ≥3 times a week, is known to 
improve clinical parameters in the short term compared 
with conventional-schedule haemodialysis (HD), 
generally 3×3.5–4 hours a week. We studied long-term 
effects of NHD and used patients on conventional HD/
haemodiafiltration (HDF) as controls.
Design Four-year prospective follow-up of patients who 
switched to NHD; we compared patients with patients on 
HD/HDF using propensity score matching.
setting 28 Dutch dialysis centres.
Participants We included 159 patients starting with NHD 
any time since 2004, aged 56.7±12.9 years, with median 
dialysis vintage 2.3 (0.9–5.1) years. We propensity-score 
matched 100 patients on NHD to 100 on HD/HDF.
Primary and secondary outcome measures Control 
of hypertension (predialysis blood pressure, number of 
antihypertensives), phosphate (phosphate, number of 
phosphate binders), nutritional status and inflammation 
(albumin, C reactive protein and postdialysis weight) 
and anaemia (erythropoiesis-stimulating agent (ESA) 
resistance).
results Switching to NHD was associated with a non-
significant reduction of antihypertensives compared with 
HD/HDF (OR <2 types 2.17, 95% CI 0.86 to 5.50, P=0.11); 
and a prolonged lower need for phosphate binders (OR <2 
types 1.83, 95% CI 1.10 to 3.03, P=0.02). NHD was not 
associated with significant changes in blood pressure or 
phosphate. NHD was associated with significantly higher 
albumin over time compared with HD/HDF (0.70 g/L/year, 
95% CI 0.10 to 1.30, P=0.02). ESA resistance decreased 
significantly in NHD compared with HD/HDF, resulting in a 
33% lower ESA dose in the long term.
Conclusions After switching to NHD, the lower need for 
antihypertensives, phosphate binders and ESA persists for 
at least 4 years. These sustained improvements in NHD 
contrast significantly with the course of these parameters 
during continued treatment with conventional-schedule HD 
and HDF. NHD provides an optimal form of dialysis, also 
suitable for patients expected to have a long waiting time 
for transplantation or those convicted to indefinite dialysis.
IntrODuCtIOn  
Nocturnal haemodialysis (NHD) has increas-
ingly become a subject of research in recent 
years, as a potential solution for the high 
cardiovascular morbidity and mortality among 
haemodialysis (HD) patients.1–3 Several 
factors are deemed responsible for this high 
risk. Recurrent states of hypervolaemia are 
known to cause left ventricular hypertrophy 
and cardiac remodelling. The consequent 
necessity of rapid fluid removal during dial-
ysis may cause hypotension and compromise 
tissue perfusion.4–6 Furthermore, continuous 
hyperphosphataemia, often in conjunction 
with hypercalcaemia and hyperparathy-
roidism, leads to vascular calcifications.7–10 
strengths and limitations of this study
 ► In this observational study on nocturnal 
haemodialysis, we used propensity-score matching 
as an expedient alternative to randomisation. 
Matched patients on nocturnal haemodialysis and 
controls were thus well comparable.
 ► Detailed data on several clinical parameters were 
collected for a long follow-up time in both cohorts 
prospectively.
 ► Primary outcomes included pill burden, which is an 
important factor in patient well-being.
 ► An important limitation is that this study was 
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NHD provides opportunity for slower fluid removal and 
increased clearance of solutes such as urea and phos-
phate,11 due to twice as long (7–8 hours) dialysis sessions.12 
Studies have shown beneficial effects of NHD on hyper-
tension13–18 and hyperphosphataemia,13 14 16–20 yet data on 
nutritional status, anaemia control and mortality are not 
consistent.14 16 19–21 In addition, as these parameters have 
not been investigated beyond 12 months of NHD treat-
ment, it is not yet known whether these improvements 
last in the long run. We followed a large cohort of patients 
that switched to NHD prospectively, and compared long-
term control of hypertension, phosphate and anaemia, 
as well as nutritional status to data collected in the same 
patients before switch to NHD. Then, we compared the 
long-term course of these parameters in NHD to a cohort 
of patients treated with conventional (3×3.5–4 hours a 
week) HD and haemodiafiltration (HDF).
MethODs
Outcomes
We studied the following four domains as primary 
outcomes: hypertension control (predialysis systolic and 
diastolic blood pressure and number of different anti-
hypertensive agents), phosphate control (phosphate 
and number of different phosphate binding agents), 
nutritional status and inflammation (albumin, C reac-
tive protein (CRP) and postdialysis weight), and anaemia 
control (erythropoiesis-stimulating agent (ESA) resis-
tance). We investigated all-cause mortality as secondary 
outcome.
Cohorts
We prospectively followed all patients who had switched 
to NHD at two major Dutch centres that offered NHD, 
as well as HD and HDF, either in-centre or at home 
with ≥7-hour HD sessions. We defined baseline as the 
date of first NHD treatment, which was any time after 
April 2004. We collected data from electronic and paper 
records, from initiation until discontinuation of NHD, 
or until 1 February 2016. Ethical approval for this study 
was waived by the Medical Ethics Committee of the VU 
University Medical Centre, Amsterdam.
As reference, we used patient data from the CONvec-
tive TRAnsport STudy (CONTRAST, NCT00205556), 
a randomised trial designed to compare online HDF 
with low-flux HD regarding cardiovascular morbidity 
and mortality. CONTRAST randomised adult patients, 
treated with low-flux HD 2–3 a time weekly for at least 2 
months with a single-pool Kt/Vurea ≥1.2 per treatment, in 
a 1:1 ratio to treatment with low-flux HD or online HDF 
and followed for 1–7 years.22 We used data of patients 
treated in the Netherlands (26 centres) with at least three 
sessions per week between June 2004 and January 2011.
Data collection
Apart from demographics and medical history, we 
collected data on clinical parameters and medication use 
at switch to NHD (baseline), and at 3, 6, 12, 18, 24, 36 
and 48 months. Also, we recorded reasons for discontinu-
ation of NHD. We recorded deaths that occurred within 3 
months after cessation of NHD.
In CONTRAST, quarterly measured data similar to the 
NHD cohort were available for up to 48 months. Although 
mortality follow-up of CONTRAST was obtained irrespec-
tive of censoring, we adjusted these data to a follow-up 
similar to the NHD cohort (within 3 months of censoring).
In both cohorts, mean values of the last week before a 
selected time point were taken for predialysis blood pres-
sure and postdialysis weight. Laboratory parameters were 
measured with routine assays. We converted albumin, 
when measured with bromocresol purple assays, to 
bromocresol green with the following formula23:
 Albuminbromcresol green = Albuminbromcresol purple + 5.5 g/L 
We converted averaged weekly ESA doses of 1 month 
to defined daily doses (DDD) with conversion factors 
provided by the WHO Drug Classification.24
Dialysis regimens
We defined NHD treatment as 3–5×8 hours weekly either 
in-centre or at home, with a lower blood flow (150–
220 mL/min), lower dialysate flow (300 mL/min) and a 
somewhat lower bicarbonate concentration compared 
with conventional HD, adjusted depending on labora-
tory results. Anticoagulation was performed with low-mo-
lecular weight heparin (dalteparin or nadroparin) for 
in-centre NHD and unfractionated heparin for home 
NHD.
We defined conventional HD and HDF treatment as 
3×3.5–4 hours a week (incidentally 5 hours), with blood 
flow rates between 300 and 400 mL/min. All patients used 
double-needle cannulation. Online HDF was performed 
in postdilution mode with a mean convection volume of 
20.7±6.0 L/hour.25 Anticoagulation was performed with 
low-molecular weight heparin.25
statistical analysis
We performed longitudinal analyses with generalised 
linear mixed models,26 with time as continuous variable 
and random intercepts and slopes when appropriate. 
CRP and ESA resistance were skewed and therefore natu-
ral-log-transformed. For practical reasons, we dichoto-
mised number of antihypertensive and phosphate-binding 
agents into 0–1 and ≥2 types; we present ORs for having 
a lower number of drugs compared with baseline 
(<2 types). We performed survival analysis with Cox 
proportional hazards regression.27 We tested for propor-
tional hazards assumptions with Schoenfeld’s residuals.
To compare the NHD cohort with the HD/HDF 
cohort, we used propensity-score matching. In order to 
estimate propensity scores28, we imputed data missing 
at baseline 25 times28 with multivariate imputations by 
chained equations.29 All variables had ≤1% missing values 
at baseline, apart from albumin (1.8%), dialysis prescrip-
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glomerular filtration rate (5.3%), cholesterol (10.8%) 
and CRP (30.7%). In each of the 25 imputed datasets, 
we matched patients on propensity of NHD treatment,30 
logistically regressed on 22 variables affecting outcome 
or treatment selection (see online supplementary mate-
rial). We matched nearest neighbours in a 1:1 ratio, 
without replacement, within a 0.1 calliper. We considered 
covariates balanced when standardised mean differences 
were <0.1.
We used multiple imputations only for propensity score 
matching. We performed longitudinal analyses for each 
matched cohort in the non-imputed dataset. We restricted 
analyses to the follow-up duration of each outcome avail-
able in the HD/HDF cohort. We pooled effect measures 
from the 25 analysed matched cohorts using Rubin’s 
rules.28 31 P values <0.05 (two-sided) were considered 
statistically significant. All analyses were performed using 
R V.3.3.3.32
sensitivity analysis
As sensitivity analysis, we repeated the multivariate 
imputations, propensity-score matching and subsequent 
analyses for NHD patients versus HD patients and NHD 
patients versus HDF patients separately, to account for 
potential benefits of HDF. As a post hoc sensitivity anal-
ysis, we adjusted for cause of end-stage renal disease 
(ESRD; being end-organ damage due to cardiovascular 
disease and diabetes mellitus), as this remained unbal-
anced after matching.
results
nhD cohort at baseline (n=159)
One hundred and fifty-nine patients from two large 
Dutch NHD centres (n=76 and n=83) were included, 
representing an urban and a rural population. None of 
the patients had been treated with HDF previously. At 
baseline, mean age was 52.0±14.6 years, 32% of patients 
were female, and median dialysis vintage was 2.5 (IQR 
0.9–5.5) years (table 1).
Twenty-nine per cent of patients were treated with home 
NHD, 86% of which used single-needle cannulation; 34% 
of in-centre NHD patients used single-needle cannula-
tion. Median standard Kt/V (calculated with Leypoldt’s 
formula33) was 3.02 (IQR 2.69–3.91). Seventy-eight 
patients discontinued NHD treatment within 2 years, due 
to renal transplantation (45%), medical reasons (23%), 
sleeping difficulties (14%), social reasons (6%), switch to 
diurnal home HD (4%) and death (8%).
baseline comparison of nhD and hD/hDF cohorts
There were notable differences between the complete 
NHD and HD/HDF cohorts at baseline (table 1). We 
matched 200 (IQR 198–202) NHD and HD/HDF patients 
on propensity of NHD treatment. In the matched NHD 
cohort, mean age was 56.7±12.9 years, and median dial-
ysis vintage was 2.3 (0.9–5.1) years at baseline. Twenty 
one per cent of patients had diabetes mellitus, and 31% a 
history of cardiovascular disease. Similar to the complete 
NHD cohort, patients were treated 7.8±0.4 hours 3.5 (IQR 
3.0–4.0) times a week. After matching, the NHD and 
HD/HDF cohorts were largely similar (table 2): age, sex, 
dialysis vintage, diabetes, history of cardiovascular disease, 
transplant waiting-list status, BMI and residual diuresis 
were balanced across both cohorts. Of note, cause of 
ESRD remained unbalanced after matching. We could 
not match 37% of the NHD cohort, mainly due to young 
age compared with the HD/HDF cohort. Hereafter, we 
refer to the matched cohorts as the NHD and HD/HDF 
cohorts.
longitudinal comparison of matched nhD and hD/hDF cohorts
In the NHD cohort, systolic and diastolic blood pressure 
did not change over time (table 3). As can be seen from 
figure 1, blood pressure fluctuated somewhat during 
the third and fourth years in the HD/HDF cohort, but 
tended to decrease overall. There was no significant 
difference in systolic or diastolic blood pressure change 
between the NHD and HD/HDF cohorts (systolic blood 
pressure change vs HD/HDF: 1.94 (95% CI −1.17 to 5.06) 
mm Hg/year, P=0.22, and diastolic blood pressure change 
vs HD/HDF: 0.31 (95% CI −1.31 to 1.93) mm Hg/year, 
P=0.71). In the NHD cohort, the number of antihyper-
tensive agents diminished substantially after switching 
to NHD; the odds of having less antihypertensive agents 
increased over time (figure 1). Although the number of 
antihypertensive agents did not change in the HD/HDF 
cohort, the change in number of antihypertensive agents 
in the NHD cohort was not significantly different from 
the HD/HDF cohort (OR of <2 types vs HD/HDF per 
year: 2.17 (95% CI 0.86 to 5.50), P=0.11).
Initially, phosphate levels decreased slightly in patients 
who switched to NHD and remained stable during 
follow-up (figure 2). In patients on HD/HDF, phosphate 
levels did not decrease significantly and fluctuated during 
follow-up. The course of phosphate in NHD was not 
significantly different from that in HD/HDF (−0.04 (95% 
CI −0.12 to 0.03) mmol/L/year, P=0.23). However, the 
number of phosphate-binding agents diminished sharply 
in patients who switched to NHD compared with patients 
on HD/HDF (OR <2 types vs HD/HDF per year: 1.83 
(95% CI 1.10 to 3.03), P=0.02, figure 2). Moreover, the 
absolute number of phosphate-binding pills decreased in 
the matched NHD cohort (from 6 at baseline (IQR 4–9) 
to 3 (IQR 0–5)) in the first 3 months after switching and 
remained stable afterwards.
In patients who switched to NHD, albumin was stable. 
Compared with patients on HD/HDF, NHD was associ-
ated with significantly higher albumin levels over time 
(0.70 (95% CI 0.10 to 1.30) g/L/year, P=0.02; figure 3). 
CRP and postdialysis weight did not change significantly 
after switching to NHD, which was not significantly 
different from patients on HD/HDF (table 3).
ESA resistance decreased in patients who switched to 
NHD (ratio per year 0.61 (95% CI 0.47 to 0.81), P<0.001), 
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Table 1 Baseline characteristics of the complete (unmatched) NHD and HD/HDF cohorts
NHD (n=159) HD/HDF (n=560) Standardised mean difference
Demographics
  Age (years) 52.0±14.6 64.0±15.2 0.79
  Male (%) 68 62 0.12
  BMI (kg/m2) 26.1±6.2 25.2±4.4 0.18
Medical history
  Dialysis vintage (years) 2.5 (0.9–5.5) 2.0 (1.0–3.8) 0.22
  Cause of ESRD (%) 
   Glomerulonephritis 24 13 0.63
   Interstitial nephritis 14 10
   Cystic kidney disease 15 8
   Congenital, other 5 1
   Renovascular 17 30
   Diabetes mellitus 9 15
   Multisystem disease 6 5
   Other 4 11
   Unknown 6 9
  Current smoker (%) 16 21 0.13
  Comorbidities (%) 
   Diabetes mellitus 21 21 0.00
   Cardiovascular disease 28 41 0.42
   Transplant waiting-list listed (%) 23 33 0.21
Phosphate control
  Phosphate (mmol/L) 1.73±0.53 1.64±0.50 0.16
  Different phosphate binding agents 1.46±0.65 1.27±0.74 0.27
  Vitamin D usage (%) 85 67 0.43
Hypertension control
  Systolic blood pressure (mm Hg) 140.4±21.2 148.1±22.2 0.36
  Diastolic blood pressure (mm Hg) 79.9±12.9 76.1±12.4 0.30
  Different antihypertensive agents 0.99±0.93 1.55±1.28 0.50
Nutritional status/inflammation
  Postdialysis weight (kg) 77.9±19.3 72.4±13.9 0.33
  Creatinine (µmol/L) 892±275 886±249 0.02
  Albumin (g/L) 40.8±2.9 40.0±3.8 0.22
  CRP (mg/L) 5.0 (2.2–12.7) 4.1 (1.4–10.8) 0.05
  Cholesterol (mmol/L) 3.9±1.1 3.6±1.0 0.26
Anaemia control
  Hb (mmol/L) 7.1±0.8 7.4±0.8 0.33
  ESA dose (DDD) 7.8 (3.9–13.3) 8.9 (4.4–13.3) 0.18
  ESA resistance index (DDD/Hb/kg/week) 0.01 (0.01–0.03) 0.02 (0.01–0.03) 0.21
  Use of iron supplementation (%) 88 75 0.34
Dialysis treatment parameters and residual kidney function
  Residual diuresis >100 mL/24 hours (%) 45 50 0.11
  Residual GFR (mL/min)* 0 (0–2.1) 0.2 (0–2.4) 0.05
  Central venous catheter (%) 10 1 0.38
  Weekly dialysis sessions 3.2±0.8 3.0±0.1 0.33
  Weekly dialysis hours 12.4±2.6 11.3±1.2 0.54
*Mean of urea/creatinine clearance, 0 when residual diuresis <100 mL/24 hours. 
We report data as mean±SD, median (IQR) or proportions where appropriate; Standardised mean differences <0.1 are considered balanced. 
BMI, body mass index; CRP, C reactive protein; DDD, defined daily dose; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; GFR, glomerular 
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Table 2 Baseline characteristics of the nocturnal haemodialysis (NHD) and haemodialysis/haemodiafiltration (HD/HDF) 
cohorts after propensity-score matching
NHD (n=100)* HD/HDF (n=100)* Standardised mean difference
Demographics
  Age (years) 56.7±12.9 56.3±15.1 0.03
  Male (%) 68 67 0.02
  BMI (kg/m2) 25.9±5.6 25.9±5.1 0.01
Medical history
  Dialysis vintage (years) 2.3 (0.9–5.1) 2.1 (1.1–4.0) <0.01
  Cause of ESRD (%) 
   Glomerulonephritis 24 16 0.54
   Interstitial nephritis 13 6
   Cystic kidney disease 16 9
   Congenital, other 4 1
   Renovascular 19 27
   Diabetes mellitus 9 16
   Multisystem disease 5 6
   Other 6 10
   Unknown 5 9
  Current smoker (%) 19 19 0.02
  Comorbidities (%) 
   Diabetes mellitus 21 19 0.02
   Cardiovascular disease 30 29 0.02
   Transplant waiting-list listed (%) 28 28 <0.001
Phosphate control
  Phosphate (mmol/L) 1.72±0.52 1.69±0.53 0.05
  Different phosphate binding agents 1.40±0.74 1.43±0.64 0.05
  Vitamin D usage (%) 84 67 0.40
Hypertension control
  Systolic blood pressure (mm Hg) 143.0±21.7 143.7±21.1 0.03
  Diastolic blood pressure (mm Hg) 79.4±13.2 79.7±12.7 0.02
  Different antihypertensive agents 1.22±1.18 1.15±0.95 0.07
Nutritional status/inflammation
  Postdialysis weight (kg) 77.5±16.8 75.5±15.4 0.13
  Creatinine (µmol/L) 863±260 938±273 0.28
  Albumin (g/L) 40.6±3.0 40.6±3.8 0.02
  CRP (mg/L) 5.0 (2.3–13.6) 3.7 (1.4–10.1) 0.02
  Cholesterol (mmol/L) 3.9±1.0 3.9±1.0 <0.01
Anaemia control
  Hb (mmol/L) 7.1±0.8 7.4±0.7 0.35
  ESA dose (DDD) 8.0 (4.4–13.3) 6.7 (4.0–13.3) 0.04
  ESA resistance index (DDD/Hb/kg/week) 0.01 (0.01–0.03) 0.01 (0.01–0.03) 0.01
  Use of iron supplementation (%) 87 86 0.01
Dialysis treatment parameters and residual kidney function
  Residual diuresis >100 mL/24 hours (%) 49 50 0.04
  Residual GFR (mL/min)† 0.0 (0.0–3.7) 0.0 (0.0–2.7) 0.08
  Central venous catheter (%) 4 5 0.04
  Weekly dialysis sessions 3.0±0.7 3.0±0.1 0.02
  Weekly dialysis hours 11.7±2.2 11.6±1.1 0.05
*M edian 200 (IQR  198 – 202)  matched cases. 
†Mean of urea/creatinine clearance, 0 when residual diuresis <100 mL/24 hours. We report data as mean±SD, median (IQR) or proportions where appropriate. 
Standardised mean differences<0.1 are considered balanced. 
BMI, body mass index; CRP, C reactive protein; DDD, defined daily dose; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; GFR, glomerular 
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of whom only 1 year’s data were available (figure 4). ESA 
resistance remained persistently low for up to 48 months 
after switching to NHD (ratio per year 0.89 (95% CI 0.83 to 
0.96), P<0.01). ESA dose was reduced from median 8.0 
(IQR 4.4–13.3) to 5.6 (IQR 2.2–8.9) DDD after 4 years of 
NHD. Additional data on iron-storage parameters in both 
cohorts (ferritin, transferrin saturation), intravenous iron 
dose and residual urine production in the NHD cohort are 
available as online supplementary material. We provide 
data on the 4-year course of clinical parameters in the 
Table 3 Effect estimates per year in the propensity-score-matched NHD and HD/HDF cohorts, and difference between the 
propensity-score-matched NHD and HD/HDF cohorts (all outcomes 48 months, except for CRP 36 months and ESA resistance 
index 12 months)
NHD HD/HDF NHD vs HD/HDF
Hypertension control ∆   P ∆ P ∆ P
Systolic blood pressure (∆ mm Hg) 0.62 (−1.74 to 2.99) 0.27 −1.32 (−3.40 to 0.76) 0.22 1.94 (−1.17 to 5.06) 0.22
Diastolic blood pressure (∆ mm Hg) −0.82 (−2.10 to 0.45) 0.21 −1.13 (−2.18 to −0.08) 0.04 0.31 (−1.31 to 1.93) 0.71
Different antihypertensive agents
(OR <2 types)
2.25 (1.12 to 4.54) 0.02 1.04 (0.55 to 1.97) 0.91 2.17 (0.86 to 5.50) 0.11
Phosphate control ∆   P ∆ P ∆ P
Phosphate (∆ mmol/L) −0.04 (−0.10 to 0.01) 0.14 0.00 (−0.05 to 0.05) 0.90 −0.04 (−0.12 to 0.03) 0.23
Different phosphate-binding agents
(OR <2 types)
1.79 (1.13 to 2.84) 0.01 0.98 (0.73 to 1.31) 0.90 1.83 (1.10 to 3.03) 0.02
Nutritional status/inflammation ∆   P ∆ P ∆ P
Albumin (∆ g/L) 0.29 (−0.14 to 0.72) 0.19 −0.41 (−0.85 to 0.03) 0.07 0.70 (0.10 to 1.30) 0.02
CRP (ratio*) 0.98 (0.91 to 1.06) 0.64 1.01 (0.90 to 1.13) 0.89 0.97 (0.84 to 1.12) 0.72
Post-dialysis weight (∆ kg) 0.09 (−0.80 to 0.98) 0.85 −0.08 (−0.86 to 0.69) 0.84 0.17 (−1.04 to 1.38) 0.78
  Anaemia control ∆   P ∆ P ∆ P
ESA resistance index (ratio*) 0.75 (0.62 to 0.91) <0.01 1.23 (1.03 to 1.46) 0.02 0.61 (0.47 to 0.81) <0.001
Effect estimates are presented with 95% CI.
*CRP and ESA resistance were modelled with a gamma-distributed log link function. Hence, the (exponentiated) coefficients should be 
interpreted multiplicatively, that is, as a ratio.
CRP, C reactive protein; ESA, erythropoiesis-stimulating agent; HD, haemodialysis; HDF, haemodiafiltration; NHD, nocturnal  HD.
Figure 1 Hypertension control in nocturnal haemodialysis versus haemodialysis/haemodiafiltration. Left: systolic (upper two 
lines) and diastolic (lower two lines) blood pressure (mm Hg) in propensity-score-matched nocturnal haemodialysis (NHD, 
dark lines) and haemodialysis/haemodiafiltration (HD/HDF, light lines) patients over the course of 48 months. Right: number of 
different antihypertensive agents in propensity-score-matched NHD (dark line) and HD/HDF (light line) patients over the course 
of 48 months. OR <2 types NHD compared with baseline P=0.02; OR <2 types NHD vs HD/HDF P=0.11. 95% CIs are shown. 
Number of NHD/HD/HDF patients available for analysis at 0 months: 100/100; 12 months: 57/74; 24 months: 35/51; 36 months: 
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complete NHD cohort (n=159) as online supplementary 
material.
Thirty three NHD patients and 26 HD/HDF of the 
matched patients received a renal transplant, while 11 
NHD patients and 23 HD/HDF patients died during a 
mean follow-up of 1.73±1.41 and 2.28±1.38 years. HR for 
all-cause mortality was 0.64 (95% CI 0.28 to 1.48; P=0.29) 
for NHD compared with HD/HDF patients.
sensitivity analysis
When matching NHD with either HD (online supple-
mentary table 1) or HDF patients (online supplementary 
table 2), similar results were obtained regarding hyperten-
sion, phosphate and anaemia control, nutritional status 
(online supplementary tables 3 and 4), and mortality 
(HR NHD vs HD 0.68 (95% CI 0.29 to 1.59); HR NHD 
vs HDF 0.65 (95% CI 0.28 to 1.49)). Also, post hoc sensi-
tivity analysis with adjustments for causes of ESRD yielded 
similar results (online supplementary table 5).
DIsCussIOn
To our knowledge, this is the first study to evaluate clin-
ical parameters in detail for several years of NHD treat-
ment. Our findings suggest that patients who switch to 
NHD experience long-term improvements of important 
clinical parameters, while benefiting from a greatly 
reduced pill burden and a lower need for ESA. As a 
randomised controlled trial for such a long follow-up is 
not feasible, with most patients refusing randomisation 
between such different dialysis modalities, we employed 
propensity score matching, the next-best method, for a 
well-founded comparison. Compared with patients who 
continued conventional treatment with HD/HDF, the 
above conclusions remained valid.
Our findings support more easily controlled hyper-
tension in patients who switch to NHD, as they tend to 
develop a prolonged lower need for antihypertensive 
agents. Although the difference was not statistically 
significant compared with HD/HDF patients (P=0.11), 
we consider the effect size clinically meaningful: NHD 
patients were over two times more likely to have their anti-
hypertensives reduced from ≥2 to 0 or 1 types. The lack of 
statistical significance may be due to the relatively small 
patient numbers and a loss of information by dichotomi-
sation into 0–1 and ≥2 types of antihypertensives. We did 
not find explicit differences in blood pressure between 
NHD and HD/HDF patients, probably because systolic 
blood pressure did not decrease significantly in our NHD 
cohort, contrasting with some previous studies.13 14 16 This 
may be explained by the heterogeneous NHD frequen-
cies in our cohort: we observed significantly lower 1-year 
blood pressures in NHD patients who dialysed >3 times/
week compared with NHD patients who dialysed ≤3 times/
Figure 2 Phosphate control in nocturnal 
haemodialysis (NHD) versus haemodialysis/
haemodiafiltration (HD/HDF). Phosphate (lines, mmol/L) and 
number of different phosphate-binding agents (bars, same 
axis) in propensity-score-matched NHD (dark lines/bars) 
and HD/HDF (light lines/bars) patients over the course of 48 
months. OR <2 types NHD compared with baseline P=0.01; 
OR <2 types NHD vs HD/HDF P=0.02. 95% CIs are shown. 
Number of NHD/HD/HDF patients available for analysis at 0 
months: 100/100; 12 months: 57/74; 24 months: 35/51; 36 
months: 20/34; 48 months: 11/22.
Figure 3 Albumin in nocturnal haemodialysis (NHD) versus 
haemodialysis/haemodiafiltration (HD/HDF). Albumin (g/L) in 
propensity-score-matched NHD (dark line) and HD/HDF (light 
line) patients over the course of 48 months. NHD compared 
with baseline P=0.19; NHD vs HD/HDF P=0.02. 95% CIs 
are shown. Number of NHD/HD/HDF patients available for 
analysis at 0 months: 100/100; 12 months: 57/74; 24 months: 
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week (data not shown). Consistent with this, a recent trial 
also did not find differences in blood pressure between 
extended-hours HD (≥24 hours during mean 3.4±0.5 
sessions weekly) and conventional treatment.34
Evidently, NHD patients also had more easily regulated 
phosphate levels. Compared with HD/HDF patients, 
patients in the NHD cohort experienced a significantly 
lower need for phosphate-binding agents during the 
48-month follow-up period. Also, the coinciding halving 
in absolute number of phosphate-binding pills in the 
NHD cohort corroborates the lower need for phos-
phate-binding agents in NHD patients, posing a great 
relief for their daily pill burden. As phosphate levels are 
often kept within target ranges35 by attending nephrol-
ogists, no outstanding differences in phosphate were 
observed. Thirty-four per cent of NHD patients had near-
normal phosphate levels (≤1.50 mmol/L) at baseline, 
compared with 52% at 12 months (with some receiving 
phosphate added to the dialysate).
As to nutritional status, we found striking differences 
between NHD and HD/HDF patients over the course 
of 48 months. In our study, NHD was associated with 
significantly higher albumin levels over time, compared 
with HD/HDF. This is in line with previous studies 
that described stable or even increasing albumin levels 
following initiation of NHD.14 16 19 CRP levels did not 
differ significantly between the NHD and HD/HDF 
patients. Postdialysis weight remained stable in NHD 
patients over the years. Contrary to what we had expected 
based on previous reports,16 19 this was not significantly 
different from HD/HDF patients, which might be 
explained by patients adopting a more active lifestyle after 
several years on NHD. NHD patients also achieved supe-
rior anaemia control compared with HD/HDF patients, 
contrasting with previous conflicting reports.13 14 16 18 19 
Although haemoglobin did not change in NHD patients, 
presumably due to adjustments of ESA and iron dosages 
according to guidelines, ESA resistance diminished 
evidently in NHD patients and remained persistently low 
for up to 4 years, against a clear increase in ESA resistance 
in the HD/HDF cohort.
Amid conflicting data, a recently published large study 
showed a lower mortality risk in patients treated with 
extended-hours dialysis compared with conventional HD 
(HR 0.67 (95% CI 0.49 to 0.93)).36 We found a remark-
ably similar lower mortality risk in NHD (HR 0.64 (95% 
CI 0.28 to 1.48)), although our study was not powered to 
prove mortality differences due to its design and conse-
quent sample size. It should be noted that no safety events 
(ie, vascular access complications) were recorded, as we 
did not expect additional complications because of the 
habit of single-needle cannulation in frequent NHD.
Remarkably, more NHD patients were transplanted 
compared with matched HD/HDF patients (32.6 vs 
26.3%), despite similar rates of transplant waiting-list 
listing at baseline. As transplanted, presumably healthier 
patients dropped out more frequently in the NHD 
cohort. This could have resulted in a somewhat less 
healthy matched cohort, which could have led to an over-
estimation (but surely no underestimation) of mortality 
hazard in the NHD cohort. The reasons for the dispa-
rate transplantation rates remain unclear. Possibly, clin-
ical improvement of non-waiting-list-listed NHD patients 
resulted in more transplant waiting-list-listed  patients.
There were limitations to this study, and the results 
should be interpreted within the limitations of this study. 
First, this study was non-randomised, and as a result, 
patients in our NHD cohort were from a selected popu-
lation, as with many other studies on NHD.17 19 We used 
propensity-score matching to reduce this selection bias, 
so that the groups were similar in baseline characteristics. 
Although causes of ESRD remained unbalanced between 
the NHD and HD/HDF cohorts after matching, a post 
hoc sensitivity analysis with adjustments for cause of ESRD 
yielded similar results, supporting the conclusions of this 
study. Second, not all NHD patients could be matched 
to HD/HDF counterparts, and this study had to compro-
mise somewhat on sample size and was underpowered 
to evaluate mortality. On the other hand, we gathered 
a large cohort of NHD patients that can be considered 
demographically representative for the Dutch NHD 
population. Third, as data on the HD/HDF cohort were 
collected in a randomised trial as opposed to the obser-
vational NHD cohort, a potential risk of information bias 
exists, although minor as clinical parameters in the NHD 
Figure 4 Erythropoiesis-stimulating agent (ESA) resistance 
in nocturnal haemodialysis (NHD) versus haemodialysis/
haemodiafiltration (HD/HDF). ESA resistance (DDD/Hb/kg/
week) in propensity-score-matched NHD (dark line) and HD/
HDF (light line) patients over the course of 48 months. NHD 
compared with baseline P<0.01; NHD vs HD/HDF P<0.001. 
95% CI are shown. Number of NHD/HD/HDF patients 
available for analysis at 0 months: 100/100; 12 months: 
57/74; 24 months: 35/0; 36 months: 20/0; 48 months: 
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cohort were assessed at standardised intervals as part of 
routine care. Also, we aimed to minimise interference 
due to different healthcare systems, by including patients 
on HD/HDF only when they were treated in Dutch dial-
ysis centres. Fourth, the NHD cohort was drawn from 
only two centres; however, we deem the potential influ-
ence of individual prescribing practices (eg, nephrolo-
gists preferentially prescribing a single type of phosphate 
binder) insignificant, considering the equal number of 
phosphate-binding agents at baseline and the coinciding 
halving in number of pills in the NHD cohort, and other-
wise uniform treatment patterns in the Netherlands. Fifth, 
the preferable method for hypertension monitoring is 
ambulatory blood pressure monitoring or self-reported 
home measurements, while we only measured predial-
ysis blood pressure. Finally, our NHD cohort comprised 
patients who performed any kind of extended-hours 
NHD, which resulted in heterogeneity of frequency and 
location. On the other hand, we accounted for potential 
benefits of HDF treatment by comparing NHD with HD 
and HDF separately, that is, sensitivity analyses. Earlier 
data from CONTRAST showed that HDF helped to 
improve phosphate control,37 38 yet not ESA resistance.39 
These sensitivity analyses yielded similar results.
Overall, our study highlights the long-term improve-
ments in important clinical parameters in patients 
switching to NHD, compared with conventional HD/HDF 
treatment. Translated to the clinic, our findings suggest 
that patients considering NHD can expect an increase 
in albumin, which is associated with lower mortality,40 a 
lower dose of ESA and a sizeable reduction in pill burden, 
which is significant for their well-being. Our findings 
imply that NHD is more than a hype: it offers the prospect 
of enduring improvements for patients on HD, also suit-
able for patients expected to have a long waiting time for 
transplantation or those convicted to indefinite dialysis.
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